Literature DB >> 12007845

Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.

T Gillespie1, R G Masterton.   

Abstract

The frequency by which resistant Pseudomonas aeruginosa strains could be selected was compared for two antibiotics, levofloxacin and ciprofloxacin. Seven distinct strains were cultured on plates containing 1x, 2x, 4x and 8x the minimum inhibitory concentration (MIC) of the antibiotic under investigation. Resistant mutants were more readily isolated by growth on culture plates that contained ciprofloxacin, and the resulting MIC of the resistant mutant was also more frequently increased. Time-kill studies on comparable strains where the MIC for both antibiotics had increased by at least fourfold showed no difference between the two agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12007845     DOI: 10.1016/s0924-8579(02)00017-1

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  3 in total

1.  In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.

Authors:  Paula King; Olga Lomovskaya; David C Griffith; Jane L Burns; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

2.  Factors influencing fluoroquinolone resistance.

Authors:  Daniel F Sahm; Clyde Thornsberry; Mark E Jones; James A Karlowsky
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

3.  Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.

Authors:  Antoine Grillon; Frédéric Schramm; Magali Kleinberg; François Jehl
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.